BURLINGTON, Mass., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc., (OTCBB:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that its common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading on Monday, December 19, 2011 under the symbol CNDO. The Company’s common stock will continue to trade on the Over the Counter Bulletin Board until the market close on Friday, December 16, 2011.
